| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1084250346 |
| P356 | DOI | 10.1186/S12879-017-2302-3 |
| P932 | PMC publication ID | 5351062 |
| P698 | PubMed publication ID | 28292280 |
| P50 | author | Marc J. M. Bonten | Q87138620 |
| Marie-Josée J Mangen | Q43015397 | ||
| G. Ardine de Wit | Q60669638 | ||
| P2093 | author name string | Susanne M Huijts | |
| P2860 | cites work | Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia | Q73476042 |
| [Costs of illness and health-related quality of life for community-acquired pneumonia--a systematic review] | Q83932555 | ||
| A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin | Q28145205 | ||
| A prediction rule to identify low-risk patients with community-acquired pneumonia | Q28301165 | ||
| Health status of the advanced elderly in six European countries: results from a representative survey using EQ-5D and SF-12 | Q34437749 | ||
| Rationale and design of the costs, health status and outcomes in community-acquired pneumonia (CHO-CAP) study in elderly persons hospitalized with CAP | Q35071890 | ||
| Cost-Effectiveness of Vaccinating Immunocompetent ≥65 Year Olds with the 13-Valent Pneumococcal Conjugate Vaccine in England | Q35935754 | ||
| Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis | Q36350368 | ||
| Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands | Q36571135 | ||
| Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults | Q37319888 | ||
| Long-term symptom recovery and health-related quality of life in patients with mild-to-moderate-severe community-acquired pneumonia | Q38985301 | ||
| Modeling valuations for EuroQol health states | Q39513119 | ||
| Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. | Q40476803 | ||
| The estimation of a preference-based measure of health from the SF-36. | Q40647897 | ||
| Using the SF-36 with older adults: a cross-sectional community-based survey | Q40691079 | ||
| The cost-effectiveness of pneumococcal vaccination in healthy adults over 50: An exploration of influential factors for Belgium | Q40751138 | ||
| Incidence, direct costs and duration of hospitalization of patients hospitalized with community acquired pneumonia: A nationwide retrospective claims database analysis. | Q40932197 | ||
| Long-term mortality and quality of life in intensive care patients treated for pneumonia and/or sepsis: Predictors of mortality and quality of life in patients with sepsis/pneumonia | Q41146123 | ||
| Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. | Q41415380 | ||
| Comparison of population health status in six european countries: results of a representative survey using the EQ-5D questionnaire | Q43702059 | ||
| Determinants of hospital costs in community-acquired pneumonia. | Q44127792 | ||
| Pneumococcal vaccination and risk of acute coronary syndromes in patients with pneumonia: population-based cohort study | Q44183473 | ||
| Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia | Q44304498 | ||
| Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients | Q45246357 | ||
| The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. | Q52037688 | ||
| Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged ≥65 years in the Netherlands | Q58879954 | ||
| The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies | Q59847735 | ||
| P433 | issue | 1 | |
| P921 | main subject | pneumonia | Q12192 |
| quality of life | Q13100823 | ||
| P304 | page(s) | 208 | |
| P577 | publication date | 2017-03-14 | |
| P1433 | published in | BMC Infectious Diseases | Q15759919 |
| P1476 | title | The impact of community-acquired pneumonia on the health-related quality-of-life in elderly | |
| P478 | volume | 17 |
| Q54268963 | Authors' reply to Gandjour: "Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany". |
| Q55431323 | Characteristics and Management of Community-Acquired Pneumonia in the Era of Global Aging. |
| Q89208315 | Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada |
| Q89840097 | Cost-Effectiveness of Pneumococcal Vaccination Policies and Uptake Programs in US Older Populations |
| Q92203872 | Cost-effectiveness of adult pneumococcal vaccination policies in underserved minorities aged 50-64 years compared to the US general population |
| Q48181732 | Disease burden of psittacosis in the Netherlands |
| Q55277513 | Estimating the cost-effectiveness of a sequential pneumococcal vaccination program for adults in Germany. |
| Q48113484 | Health related quality of life in patients with community-acquired pneumococcal pneumonia in France |
| Q97418370 | Incidence, mortality, and lethality of hospitalizations for community-acquired pneumonia with comorbid cardiovascular disease in Spain (1997-2015) |
| Q52806130 | Long-term sequelae of acute respiratory distress syndrome caused by severe community-acquired pneumonia: Delirium-associated cognitive impairment and post-traumatic stress disorder. |
| Q93027471 | Patient-Reported Consequences of Community-Acquired Pneumonia in Patients with Chronic Obstructive Pulmonary Disease |
| Q92356011 | Patient-reported outcome measurement in community-acquired pneumonia: feasibility of routine application in an elderly hospitalized population |
| Q89451260 | Pneumococcal Vaccination in Adults Aged ≥65 Years: Cost-Effectiveness and Health Impact in U.S. Populations |
| Q57472259 | The association between major complications of immobility during hospitalization and quality of life among bedridden patients: A 3 month prospective multi-center study |
| Q50089562 | Toxic alcohol diagnosis and management: an emergency medicine review |
Search more.